| 常用名 | CPI-0610 | CAS号 | 1380087-89-7 |
|---|---|---|---|
| 价格 | ¥需询单/1g ¥需询单/1g ¥需询单/1mg | 纯度 | 98.0% |
| 备货期 | 需询单 | 库存 | 询单 |
| 产品详情(用途,包装等)
用途: CPI-0610 is a potent, selective, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 with IC50 of 39 nM in time-resolved fluorescence energy transfer (TR-FRET ) binding assay. IC50 value: 39 nMTarget: Bromodomains in vitro: CPI-0610 is about 6 times more potent against BET BD-2 than against BET BD-1. When tested on other members of the bromodomain family, CPI-0610 is remarkably selective, displaying essentially no activity in TR-FRET- or AlphaLisa-based assays against the bromodomains of CBP, BRD9, BRPF1, PCAF, BRG1, ATAD2, TRIM24, BRD8 (IC50 of >20 μM, >80 μM, >20 μM, >20 μM, >20 μM, >80 μM, >20 μM, and >15 μM, respectively), among others. In a CEREP express panel of about 50 GPCRs, ion channels, and transporters, the compound displayed no meaningful inhibition. CPI-0610 also displays negligible inhibition of cytochrome P450 activity when tested at 10 μM against a number of common isoforms, and it also showed no time-dependent inhibition.[1] in vivo: The t1/2 of CPI-0610 for the rat and dog is 0.93 and 9 h, respectively.[1] 作用: 体外活性:CPI-0610在细胞因子存在下抑制MM(多发性骨髓瘤)细胞生长,并与骨髓基质细胞共培养。 CPI-0610诱导与MYC下调相关的细胞凋亡和G1细胞周期停滞。 然而,在BET抑制时,MM细胞中BCL2,NF-κB和MCL1的蛋白质水平保持不变。 CPI-0610抑制MM细胞中转录和蛋白水平的Ikaros和IRF4表达。 体内活性:在使用MV-4-11急性髓细胞白血病细胞的小鼠异种移植模型中,与载体对照相比,CPI-0610处理的小鼠的MYC mRNA水平在4小时时显着降低,并且在稍后的时间点朝向对照水平恢复。 对应于血浆中化合物的游离浓度降低。 CPI-01610的BET溴结构域抑制导致在所检查的时间段内肿瘤生长的显着抑制(分别为41%,80%和74%肿瘤生长抑制),在动物中没有任何显着的体重减轻。 根据大鼠和狗的可接受的毒性特征,在两个物种中观察到一组常见的毒性:淋巴耗尽; 骨髓的低细胞性与相关的贫血和血小板减少症有关; 胃肠道粘膜萎缩,糜烂和溃疡; 睾丸生精上皮变性; 和轻度至中度的高血糖症。 这些毒性是可逆的。 物理化学性质: CAS号:1380087-89-7 常用中文名:CPI-0610 常用英文名:CPI-0610 分子式:C20H16ClN3O2 分子量:365.813 密度:1.4±0.1 g/cm3 沸点:622.8±55.0 °C at 760 mmHg 熔点:N/A 闪点:330.5±31.5 °C 储存条件:2-8℃ |